About 15 percent of adults in the US, or around 37 million people, are estimated to have chronic kidney disease, according to the Centers for Disease Control. There are very few therapeutic options for them, which means they often progress to kidney failure, which is treatable only with dialysis or transplant.
Chinook Therapeutics is looking to develop new treatments to keep people from reaching this expensive and debilitating end stage, using new lab tools that weren’t available a decade ago.
Backed by a $65 million Series A round led by Versant Ventures, Vancouver, BC-based Chinook Thursday unveiled plans to have multiple… Read more »
UNDERWRITERS AND PARTNERS